The role of cytokines in ovarian cancer drug resistance
Open Access
- 19 September 2025
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 158 (4) , 821-834
Abstract
Ovarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. While significant advances have been made in treating various types of cancer, progress in ovarian cancer treatment over the past 20 years has been minimal, and the treatment course of ovarian cancer is not linear. Although many patients initially respond to treatment and may experience tumor regression, 80% of patients relapse after one or multiple chemotherapy sessions. Cytokines play a crucial role in driving tumor progression, relapse, and drug resistance in ovarian cancer. The knowledge of ovarian cancer drug resistance and the function of cytokines in the development of tumor resistance is currently the subject of numerous relevant studies; meanwhile, the specific molecular pathways are being unearthed. Herein, we summarize the recent advancements in cytokine‐associated ovarian cancer drug resistance. In addition, we also present the cytokine targeting drugs in ameliorating ovarian cancer drug resistance. As multi‐effect factors, cytokines can induce multiple pathways to promote tumor progression and overcome extremely complex and heterogeneous living environments. From the perspective of various paths of cytokine function, the emergence of multi‐target drugs might be more promising for conquering ovarian cancer chemotherapy drug resistance.Keywords
Funding Information
- National Natural Science Foundation of China (82104289)
This publication has 136 references indexed in Scilit:
- G‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumorsFEBS Open Bio, 2022
- Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian CancerTargeted Oncology, 2021
- Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cellsActa Pharmaceutica Sinica B, 2019
- Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovaryMolecular Carcinogenesis, 2015
- Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approachesCancer and Metastasis Reviews, 2014
- Involvement of autophagy in cervical, endometrial and ovarian cancerInternational Journal of Cancer, 2013
- Mixed‐polarization phenotype of ascites‐associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapseInternational Journal of Cancer, 2013
- Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signalingJournal of Cancer Research and Clinical Oncology, 2008
- CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cellsCancer Chemotherapy and Pharmacology, 2008
- TNF-α in promotion and progression of cancerCancer and Metastasis Reviews, 2006